Dr Girard on PROs From the LUMINOSITY Trial in c-Met–Overexpressing NSCLC

Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie, discusses patient-reported outcomes (PROs) from the phase 2 LUMINOSITY trial (NCT03539536), which is evaluating telisotuzumab vedotin (Teliso-V) in patients with c-Met protein–overexpressing, EGFR wild-type, nonsquamous non–small cell lung cancer (NSCLC). Notably, these data were shared at the 2024 ESMO Annual Congress.

In the LUMINOSITY trial, patients received Teliso-V monotherapy at a dose of 1.9 mg/kg every 2 weeks. The overall response rate (ORR) was 28.6% among patients in the c-Met–overexpressing group; those in the c-Met–high population experienced a slightly higher ORR of 34.6%.

In the PRO portion of the investigation, assessment of PROs occurred every 4 weeks, prior to clinical evaluation or dosing, using European Organisation for Research and Treatment of Cancer QOL questionnaires. PROs offer a valuable perspective by evaluating both efficacy and safety, Girard begins, saying they allow for an understanding of how treatment affects cancer-related symptoms and any adverse effects (AEs) that patients experience. From the LUMINOSITY trial, patient-reported improvements were seen in key symptoms, such as dyspnea, cough, and chest pain, he highlights, noting that these improvements are linked to the high response rates observed with Teliso-V. However, there was also a noted deterioration in peripheral neuropathy, an expected AE associated with the treatment, which was mostly reported to be grade 1 and 2 severity; this deterioration was also reported in approximately 10% of patients with grade 3 or higher peripheral neuropathy, Girard notes.

The analysis of PROs from the LUMINOSITY trial reveals that quality of life (QOL) and physical functioning were generally maintained during treatment with Teliso-V, he continues. One significant finding from this analysis was the prolonged time to deterioration in QOL, which was observed in patients who responded to treatment, as well as in those with stable disease, Girard expresses. This extended time to deterioration highlights the delicate balance between efficacy and safety in this treatment setting, he notes.

In this late-line treatment setting, where patients are often fragile due to disease progression after first-line therapies and residual AEs from those treatments, Teliso-V demonstrates a strong signal of efficacy, he continues. This reinforces the importance of disease stabilization, which may not be fully appreciated in traditional response analyses but holds significant value for patients with NSCLC by contributing to a better QOL, Girard concludes.